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Background/Aims: It remains to be determined whether switching from adefovir (ADV) to tenofovir (TDF) provides 
better virological outcomes in patients exhibiting suboptimal responses to ADV plus nucleoside analogue (ADV+NA) 
therapy for NA-resistant chronic hepatitis B (CHB).
Methods: In this prospective trial, patients who showed partial responses (defined as serum hepatitis B virus [HBV] DNA 
>60 IU/mL) to ADV+NA therapy for NA resistance were randomly allocated to receive TDF plus NA (TDF+NA group, n=16) 
or to continue their current therapy (ADV+NA group, n=16). The primary end point was the proportion of patients with 
complete virological response (CVR, defined as serum HBV DNA <60 IU/mL) at 48 weeks.
Results: The median age was 52 years (16 men), and 28 were positive for hepatitis B e antigen (HBeAg). The baseline 
characteristics did not differ significantly between the two groups. The proportion with CVR was significantly higher in 
the TDF+NA group than in the ADV+NA group at 24 weeks (81.3% vs. 25.0%, P=0.001) and 48 weeks (87.5% vs. 37.5%, 
P=0.002). Furthermore, a decrease in the serum HBV DNA level of >2log10 IU/mL was more likely in the TDF+NA group at 
both 24 and 48 weeks (68.8% vs. 56.3%, P=0.014 vs. 81.3% vs. 56.3%, P=0.001, respectively). During the follow-up, the 
rate of HBeAg seroconversion was higher in the TDF+NA group than the ADV+NA group (12.5% vs. 6.25%, P=0.640), as 
was that for the hepatitis B surface antigen (6.25% vs. 0%, P=0.080). No serious adverse events due to antiviral agents 
occurred. 
Conclusions: In patients exhibiting suboptimal responses to ADV+NA therapy for NA-resistant CHB, switching from ADV 
to TDF might provide better virological outcomes. (Clin Mol Hepatol 2016;22:443-449)
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INTRODUCTION 
Chronic hepatitis B (CHB) infection is a leading cause of devel-
opment of liver cirrhosis and/or hepatocellular carcinoma (HCC).1 
Since the high serum HBV DNA level indicating active virus repli-
cation has been identified as an independent risk factor for devel-
opment of cirrhosis and HCC in two large-scale studies,2,3 the 
treatment of goal in the current era of antiviral therapy is sus-
tained suppression of viral replication through antiviral therapy.4 
For this goal, recent antiviral agents with good potency and safe-
ty, tolerability, and convenience to increase adherence was con-
tinuously developed. 
Since lamivudine (LAM), a first-generation oral nucleoside ana-
logue (NA) were available in 1998, the paradigm of CHB treat-
ment has been changed substantially. Actually, the use of LAM 
had significantly reduced the incidence of hepatic events in pa-
tients with advanced fibrosis or compensated cirrhosis.5 However, 
such a clinical benefit may be substantially offset by a high rate of 
resistance of up to 80%.6,7 The incidence rates of telbivudine re-
sistance were 4.4% at year 1 and 21.6% at year 2 in HBeAg posi-
tive CHB patients, and 2.7% at 1 year and 8.6% at year 2 in 
HBeAg negative CHB patients.8,9 Virological breakthrough with 
rtM204V/I mutations occurred in 4% at year 1 and 20% at year 2 
in CHB patients with clevudine.10 For those who developed resis-
tance to NAs including LAM, telbivudine or clevudine, the adverse 
effects of HBV drug resistance mutations may be overcome by the 
addition of adefovir dipivoxil (ADV).11 However, according to the 
study conducted in Korea, complete virological response (CVR) 
was achieved only in 32.4% during ADV and LAM combination 
(referred as ADV+NA) therapy in LAM-resistant patients.12 In an-
other study, cumulative rates of CVR were 29.9% at 1 year and 
86.9% at 5 years by ADV+NA therapy.13 Therefore, for patients 
who did not achieve CVR during ADV+NA therapy for NA-resis-
tant strains, appropriate alternative regimens to achieve the bet-
ter CVR rates should be required based upon the current para-
digm of CHB treatment.
On the other hand, tenofovir disoproxil fumarate (TDF), a very 
potent antiviral agent with a high genetic barrier, showed the ex-
cellent virologic responses in treatment-naïve patients and even in 
patients with genotypic resistance.14-16 However, for patients with 
suboptimal response despite ADV-based rescue therapy, there 
have been only few retrospective reports regarding the antiviral 
efficacy of TDF-based therapy, so far. Recently, Cho et al.17 
showed the overall virological responses of about 85 % through 
TDF-based rescue therapy monotherapy in CHB patients with sub-
optimal responses to rescue therapy for prior LAM resistance Fur-
thermore, Yang et al.18 compared the antiviral efficacy between 
switching to TDF monotherapy and continuous add-on therapy, 
showing the superior outcomes of TDF monotherapy. 
Here, in this prospective study, we aimed to directly compare 
the antiviral efficacy between switching to TDF and NA combina-
tion (referred as TDF+NA) therapy and continuation of current 
ADV+NA therapy among patients who showed suboptimal re-
sponse to ADV+NA therapy for NA-resistant CHB.
MATERIAL AND METHODS
Study subjects
Between March 2012 and February 2014, patients were en-
rolled from five tertiary referral hospitals in Korea. Patients with 
CHB (defined as positive serum hepatitis B surface antigen [HB-
sAg] test for at least 6 months) were considered eligible for enrol-
ment. Inclusion criteria were as follows; 1) confirmed mutations in 
the hepatitis B virus (HBV) polymerase gene that confers resis-
tance to NAs (LAM 100 mg, telbivudine 600 mg, entecavir 0.5 
mg or clevudine 30 mg/d orally), 2) suboptimal response (defined 
as serum HBV DNA level ≥60 IU/mL) after ADV 10 mg/d 
orally+NA therapy for at least 6 months. Exclusion criteria were 
as follows; 1) less than 20 years old, 2) previous or current history 
of HCC, 3) prior treatment with antiviral agent other than NAs 
and/or ADV, 4) decompensated liver disease, 5) co-infection with 
other viral hepatitis or other current liver diseases, 6) ADV resis-
tance mutation, 7) concurrent systemic corticosteroids or other 
immunosuppressive agents, 8) history of alcohol or substance 
abuse, 9) prior organ transplantation, and 10) a history of malig-
nancy within 3 years. The analysis in this study is based on inten-
tion-to-treat. 
This study was approved by independent institutional review 
boards and conformed to the ethical guidelines of the 1975 Hel-
sinki declaration. Written informed consent was obtained from 
patients or responsible family members.
Study designs
This study was a multi-center, randomized, open-label trial 
(ClinicalTrials.gov, ID number NCT01595633). Patients were ran-
domly allocated at 1:1 to receive TDF (300 mg q.d)+NA therapy 
(TDF+NA group) (n=16) or to continue current ADV+NA therapy 
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(ADV+NA group) (n=16). Patients were followed-up for 48 weeks 
after randomization. Randomized patients were evaluated at 
baseline and week 24 and 48 (Fig. 1). At each visit, complete 
blood counts, biochemistry, and prothrombin time were assessed. 
HBV DNA level was checked at baseline and week 24, and 48, us-
ing a polymerase chain reaction assay (Amplicor HBV Monitor 
Test, 20 IU/mL detection limit; Roche Diagnostics, Basel, Switzer-
land). Resistance mutations to NAs and ADV were evaluated us-
ing restriction fragment mass polymorphism (RFMP) assays at 
baseline and in case of necessity. Hepatitis B e antigen (HBeAg) 
and anti-HBe were assessed at baseline and at week 48, using 
commercially available enzyme immunoassays (Abbott Laborato-
ries). The upper limit of normal of alanine aminotransferase (ALT) 
was defined as 40 IU/L. Occurrences of adverse events were as-
sessed at every visit during follow-up period.
Cirrhosis was defined as follows: 1) platelet count <100,000/μL 
and ultrasonographic findings suggestive of cirrhosis, including a 
blunted, nodular liver edge with splenomegaly (>12 cm); 2) asci-
tes, esophageal or gastric varices, or hepatic encephalopathy; or 
3) overt complications of cirrhosis.
Table 1. Baseline characteristics
Variables All (n=32) ADV+NA (n=16) TDF+NA (n=16) P-values
Demographic variables
  Age, years 51.5 (46.5-59.3) 53.5 (42.0-59.3) 51.0 (48.0-59.0) 0.972
  Male gender 16 (50.0) 10 (62.5) 6 (37.5) 0.157
  Cirrhosis 12 (37.5) 8 (50.0) 4 (25.0) 0.144
Laboratory variables
  WBC, /µL 5,130 (4,263-6,008) 4,945 (4,048-6,008) 5,150 (4,400-6,280) 0.718
  Hemoglobin, g/dL 14.0 (13.0-16.0) 14.5 (12.3-16.0) 14.0 (13.0-15.8) 0.215
  Platelet, /µL 167.0 (133.0-187.0) 173.0 (133.0-193.0) 162.0 (123.0-251.0) 0.739
  PT INR 1.0 (1.0-1.0) 1.0 (1.0-1.0) 1.0 (1.0-1.0) -
  Albumin, g/dL 4.0 (3.0-4.0) 4.0 (3.0-4.0) 3.5 (3.0-4.0) 0.085
  AST, IU/mL 26.0 (21.0-30.0) 27.0 (19.0-32.0) 25.0 (22.0-30.0) 0.449
  ALT, IU/mL 26.0 (22.0-35.0) 26.0 (23.0-39.0) 25.0 (16.0-34.0) 0.595
  Total bilirubin, mg/dL 1.0 (1.0-1.0) 1.0 (0.7-1.0) 1.0 (1.0-1.0) -
  ALP, IU/L 71.0 (55.0-151.0) 66.5 (50.3-144.0) 72.0 (59.0-163.0) 0.077
  Cholesterol, mg/dL 163.0 (148.0-184.0) 159.0 (146.0-181.0) 168.0 (149.0-202.0) 0.972
Viral laboratory variables
  HBV DNA, log10 IU/mL 4.2 (3.4-5.0) 4.6 (3.8-5.1) 3.7 (3.3-4.8) 0.005
  HBe Ag positive 28 (87.5) 14 (87.5) 14 (87.5) 0.593
Previous antivirals
  Telbivudine 14 (43.8) 5 (31.3) 9 (56.3)
  Lamivudine 9 (28.1) 5 (31.3) 4 (25.0)
  Entecavir 9 (28.1) 6 (37.5) 3 (18.8)
Values are expressed as median (interquartile range) or n (%). 
ADV, adefovir dipivoxil; TDF, tenofovir disoproxil fumarate; NA, nucleoside analogue; WBC, white blood cell; PT, prothrombin time; INR, international normalized 
ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen. 
Figure 1. Recruitment algorithm for the study population.
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Definitions of study endpoints
The primary endpoint was the proportion of patients with viro-
logical response (VR, defined as serum HBV DNA level <60 IU/
mL). Secondary endpoints were the proportion of patients with 
VR at week 24, change in serum HBV DNA level from baseline at 
week 24 and 48, the proportion of patients with normalized se-
rum ALT levels, HBeAg loss or seroconversion at week 48, and 
emergence of resistance mutation to drugs during study period.
Statistical analysis
Data are expressed as the median (interquartile range [IQR]), or 
n (%) as appropriate. Differences among continuous and categor-
ical variables were examined for statistical significance with Stu-
dent’s t -test (or Mann-Whitney test, if appropriate) and chi-
squared test (or Fisher’s exact test, if appropriate). Paired related 
data were analyzed using the Wilcoxon paired test. A two-sided 
P value <0.05 was considered to indicate statistical significance. 
Statistical analyses were performed using IBM SPSS ver. 20.0 (IBM 
Co., Armonk, NY, USA)
RESULTS
Baseline characteristics of patients
After eight patients were failed with screening, a total of 32 pa-
tients were analyzed for statistical analysis. The baseline charac-
teristics of the study subjects are summarized in Table 1. The me-
dian age was 51.5 years (men, n=16). HBeAg positivity was 
identified in 28 (87.5%) patients and the median serum HBV DNA 
level was 4.2 (IQR 3.4-5.0) log10 IU/mL. Twelve (37.5%) patients 
had cirrhosis. The baseline characteristics between two groups 
were similar. 
Virological outcomes
The efficacy of treatment in ADV+NA and TDF+NA groups are 
summarized and compared in Table 2 and Figure 2. During treat-
ment, the proportions of patients with VR (defined as HBV DNA 
level <60 IU/mL or 300 copies/mL) in TDF+NA group at week 24 
and 48 were higher compared to those in ADV+NA group; 81.3 
vs. 25.0% at week 24 (P=0.001) and 87.5 vs. 37.5% at week 48 
(P=0.002). 57.1% (16/28) of HBeAg positive and 25.0% (1/4) of 
Figure 2. Proportion of patients who achieved VR at week 24 or 48 in 
the TDF+NA and ADV+NA groups. VR, virological response; NA, nucleo-
side analogue; ADV, adefovir dipivoxil; TDF, tenofovir disoproxil fumarate.
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Table 2. Virological outcomes during the follow-up period
ADV+NA TDF+NA P-values
Serum HBV DNA level at week 24, log10 IU/mL 3.5 (2.3-4.2) 1.3 (1.3-1.3) 0.001
Serum HBV DNA level at week 48, log10 IU/mL 3.2 (1.3-4.5) 1.3 (1.3-1.3) 0.004
VR at week 48 6 (37.5) 14 (87.5) 0.002
VR at week 24 4 (25.0) 13 (81.3) 0.001
Decrease in serum HBV DNA level of > 2log10 from baseline at week 24 9 (56.3) 11 (68.8) 0.014
Decrease in serum HBV DNA level of > 2log10 from baseline at week 48 9 (56.3) 13 (81.3) 0.001
HBeAg loss 1 (6.25) 2 (12.5) >0.05
HBsAg loss 0 (0) 1 (6.25) >0.05
Values are expressed as median (interquartile range) or n (%).
ADV, adefovir dipivoxil; NA, nucleoside analogue; TDF, tenofovir disoproxil fumarate; HBV, hepatitis B virus; VR, virological response; HBeAg, hepatitis B e 
antigen; HBsAg, hepatitis B surface antigen.
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HBeAg negative CHB patients were achieved VR at week 24. Fi-
nally, 75.0% of HBeAg positive and 25.0% of HBeAg negative 
CHB patients were achieved VR at week 48. 
At week 24, 9 (56.3%) patients in ADV+NA group and 11 
(68.8%) in the TDF+NA group showed the decrease in serum 
HBV DNA level of more than 2log10 from baseline (P=0.014). At 
week 48, 9 (56.3%) patients in ADV+NA group and 13 (81.3%) 
in the TDF+NA group showed the decrease in serum HBV DNA 
level of more than 2log10 from baseline (P=0.001). 
There was no patient with virologic non-response (defined as 
decrease in serum HBV DNA level of <1log10 at week 24 or 48 
from baseline).
Biochemical and serologic response
The proportion of patients with normal ALT levels at week 48 
did not differ significantly between two groups. Among patients 
with elevated ALT at baseline, all patients in ADV+NA and 
TDF+NA group achieved normalization of ALT at 48 week. 
Among patients with positive HBeAg, two (12.5%) patients in 
ADV+NA group and one (6.25%) in TDF+NA group showed 
HBeAg loss at week 48. Only one patient in ADV+NA group 
showed HBsAg loss during treatment. 
Safety
Most enrolled patients were well-tolerated during treat-
ments. The serious adverse event due to antiviral agents such 
as renal failure, lactic acidosis or worsening liver function was 
not reported. No patients required dose reduction or discontin-
uation of treatment due to adverse events. No patient experi-
enced ALT flare of more than 10 times of upper normal limit. 
There was no patient who experienced decompensated cirrho-
sis or hepatocellular carcinoma during treatment period. 
DISCUSSION
ADV add-on therapy has been widely used as a rescue thera-
py for patients with LAM-resistant CHB,19,20 because switching 
to ADV or entecavir could induce multidrug resistance. In par-
ticular, especially when TDF was unavailable, ADV add-on 
therapy has been regarded as a standard treatment option for 
those patients. However, because of the weak antiviral activity 
of ADV and poor susceptibility for drug-resistant viral strains, 
suboptimal response has been commonly observed in patients 
who received ADV+NA therapy.21-23 The VR of ADV+NA thera-
py in patients with higher baseline HBV DNA was lower than 
those with a lower baseline HBV DNA at month 12 (7.1% vs. 
66.7%).23 The persistence of suboptimal response during long-
term antiviral treatment is associated with the emergence of 
multi-drug resistant viral strains.24,25 Thus, so far, management 
of a suboptimal response to antiviral therapy has been an im-
portant issue. In this clinical context, we prospectively com-
pared the antiviral efficacy of ADV+NA and TDF+NA therapy 
among patients who have suboptimal response to ADV+NA 
therapy for NA-resistant CHB.
We found that patients with TDF+NA group are more likely to 
achieved VR compared to ADV+NA group after week 48 of treat-
ment and that TDF+NA group are more likely to experience the 
suppression of serum HBV DNA level of 2log10 from baseline. Also, 
in terms of serological response, the proportions of HBsAg and 
HBeAg seroconversion were better in TDF+NA group without sta-
tistical significance. 
Our study has several strengths. First, there was little research to 
compare between ADV+NA and TDF+NA especially for the subop-
timal responder. Although the number of patients was small, the 
effect of switching ADV to TDF in patients who showed suboptimal 
response was prospectively investigated. Second, this study fo-
cused on Korean patients, most of whom have genotype C.26 Be-
cause TDF use was approved relatively late in Asia, there have been 
less data regarding TDF use compared to Western countries.  
TDF is a potent and selective inhibitor of HBV DNA polymerase-
reverse transcriptase. TDF has been shown to produce potent viral 
suppression in large phase 3 clinical trials among treatment-naïve 
patients, and, to date, no TDF-specific resistance mutations have 
been identified. Previous study compared antiviral efficacy be-
tween ADV and TDF for NA-naïve patients, showing that patients 
treated with TDF had the higher proportion of suppression of se-
rum HBV DNA level (HBV DNA <400 copies/mL) at 48 weeks 
(13% vs. 76% for HBeAg-positive patients and 63% vs. 93% for 
HBeAg-negative patients, respectively).21 In patients with LMV re-
sistance, switching to ADV monotherapy results in higher rates of 
developing resistance to ADV than adding ADV in combination 
with LMV.27 Add-on combination therapy with LMV+ADV was 
shown to be effective in LMV resistant patients but only when ini-
tiated during the early stages of resistance development.28 Ac-
cording to the guideline in Korea,29 there are still several options 
such as LMV+ADV, LMV+TDF, ADV+NA (except LMV), TDF+NA 
(except LMV) or switching to TDF for patients with LMV resis-
448 http://www.e-cmh.org
Clin Mol Hepatol
Volume_22  Number_4  December 2016
https://doi.org/10.3350/cmh.2016.0037
tance. Recently, switching to TDF monotherapy for the LMV resis-
tance patients show effective virological suppression and does 
not appear to increase the risk of TDF resistance.18 TDF monother-
apy induced a potent and long-lasting antiviral response in NA-
experienced patients with previous treatment failure.15 So, further 
studies are required to compare the results of TDF+NA therapy vs. 
TDF monotherapy for patients with suboptimal response to 
ADV+NA, in terms of cost-effectiveness. 
There are a few limitations of our study. First, even though con-
duceted in the prospective manner, this study has small sample 
size. It could lead to potential selection bias and weak statistical 
power. The original target number of this study was 124. Howev-
er, during the study period, the reimbursement policy of the Na-
tional Health Insurance Service in the Republic of Korea had 
changed, so, it was difficult to enroll patients further. Thus, we 
finished the study as a pilot study. Second, follow-up duration 
was not long enough to observe serological outcomes between 
two regimens. Further studies with sufficient sample size and lon-
ger follow-up duration are needed. Third, there is no data regard-
ing switching to TDF monotherapy from ADV+NA therapy. Ac-
cording to the study,30 treatment efficacy of TDF alone or 
TDF+LAM therapy was not different. 
In conclusion, this trial demonstrated that switching from 
ADV+NA to TDF+NA therapy in NA-resistant CHB patients with 
suboptimal response resulted in superior VR. TDF+NA therapy 
could be a therapeutic option for patients who showed subopti-
mal response with ADV+NA. However, further studies with more 
patients should be continuously investigated for CHB patients.
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